USPTO serial 79240483
SEACH MEDICAL CANNABIS GROUP SINCE 2008
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- STRUCK, ROBERT J
- Law office
- TMEG LAW OFFICE 109 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with SEACH MEDICAL CANNABIS GROUP SINCE 2008?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Acetaminophen; anti-cancer preparations; antiallergic medicines; biological preparations for the treatment of cancer; biological preparations for the treatment of post-traumatic stress disorder; diagnostic preparations for medical purposes for detecting the presence of malignant, inflammatory and autoimmune disorders and conditions and tissue trauma in humans; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents in the form of a coating for slow release that facilitate the delivery of a wide range of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug test kits consist of medical reagents and diagnostic tests for body fluids; flower essences for medical purposes for the treatment of pain; gastrointestinal cleaning agents; glaucoma agents; herb teas for medicinal purposes; herbal extracts for medicinal purposes; drugs and medications to treat and promote the recovery from tendon injury in muscles and sports injuries; medications for the treatment of cancer; medicated preparations for skin treatment; medicinal drinks; medicated hair care preparations; hair growth stimulants for medical purposes; medicinal herbs; medicinal herbs in dried or preserved form; drug infusion for the treatment of pain; medicinal oils; oral medicine in the form of aerosols, drops, capsules, tablets and compressed tablets; medications for the treatment of infectious diseases and for the use of oncology; medicinal preparations for pain relief; medicinal radix glycyrrhizae; medicinal roots; medicinal tea used for the treatment of pain; medicines for the treatment of gastrointestinal diseases; medications for the treatment of gastrointestinal disorders; molecular complex for medicinal, surgical, therapeutic or veterinary purposes; natural remedy preparations for the treatment of gastrointestinal conditions, hormonal and chemical imbalances, and sleep disorders; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculoskeletal system, the genitourinary system, for the treatment of inflammatory disorders, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; pharmaceutical products for the prevention and treatment of cancer; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical products for treating respiratory diseases and asthma; preparation for the relief of pain; preparations for the treatment of asthma; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; processed bee pollen and honey for medicinal or therapeutic purposes; processed cactus for medicinal or therapeutic purposes; propolis for medicinal or therapeutic purposes; radioactive substances for use in nuclear medicine; radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; solutions for medical and clinical use in storing and treating cells, blood and blood components; sugar replacement for medicinal or therapeutic purposes; sweets for medicinal purposes; test strips for measuring different blood parameters when using cannabis; transdermal patches featuring botanical substances; veterinary preparations, namely, pain relief medication; all the aforesaid goods include cannabis | ACTIVE | — |
| 042 | Development services of varieties of cannabis plant and a method for developing improved cannabis varieties; services for developing methods for improving varieties of cannabis plant; development of a method of matching a variety of cannabis to the treatment of specific disease; services for developing methods for growing cannabis plant; development a methods of matching a varieties for a treatment of diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 3, 2020 | FINT | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jun 17, 2020 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jun 17, 2020 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 6, 2020 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 19, 2020 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 19, 2020 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jun 17, 2019 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jun 17, 2019 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Nov 24, 2018 | RFNT | REFUSAL PROCESSED BY IB | — |
| Nov 5, 2018 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 5, 2018 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 20, 2018 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 19, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 12, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 21, 2018 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 17, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 17, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 17, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 13, 2018 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |